Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in Pediatric ADHD with Comorbid ODD
NCT00192023Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2004
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), sponsored by Eli Lilly and Company. Started Oct 2004; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)oppositional defiant disorder (ODD)
Beyond the preview
Go deeper on NCT00192023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00192023.